In breast cancer, a low-dose anti-VEGFR antibody (DC101) treatment normalized tumor vasculature by reconditioning the tumor vessels for improved perfusion, which are homogeneously distributed within the tumor in vivo [177]. This evidence concerns the gene KDR and neoplasm.